Prof Dennis Slamon presents data from the MONALEESA-3 trial during a press conference at the 2019 ESMO congress.
This was a trial looking at treatment with the CDK4/6 inhibitor ribociclib plus fulvestrant in postmenopausal patients with HR HER2- advanced breast cancer.
Watch Prof Slamon's interview with ecancer here.
Read more on this study here.